NCT00802945 - Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

January 31, 2012

Conditions

TumorBreast Cancer

Interventions

DRUG

NKTR-102

NKTR-102 given on a q14 day schedule

DRUG

NKTR-102

NKTR-102 given on a q21 day schedule

Trial Locations (19)

2610

GasthuisZusters Antwerpen, Wilrijk

2650

UZ Antwerpen, Edegem

4000

CHU de Liege, Liège

9000

De Pintelaan 1885, Ghent

22908

University of Virginia Health System, Charlottesville

32224

Mayo Clinic Jacksonville, Jacksonville

40207

Louisville Oncology Clinical Research Program, Louisville

55905

Mayo Clinic Rochester, Rochester

92270

Desert Hematology Oncology Medical Group, Rancho Mirage

95204

Stockton Hematology/Oncology, Stockton

90089-9177

USC Norris Comprehensive Cancer Center, Los Angeles

02915

Pharma Resource, East Providence

2-2-541-72-26

Institut Jules Bordet, Brussels

CH63 3J7

Clatterbridge Centre for Oncology, Bebington

CH14 2TL

Velindre Hospital, Cardiff

G12 ONY

Beatson Oncology Center, Glasgow

LS97TF

St James University Hospital, Leed

NG5 1PB

Nottingham City Hospital, Nottingham

S10 2SJ

Weston Park Hospital, Sheffield